BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/6/2017 9:08:00 AM | Browse: 1219 | Download: 2827
 |
Received |
|
2016-07-06 09:49 |
|
Peer-Review Started |
|
2016-07-09 15:17 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2016-09-09 16:43 |
|
Revised |
|
2016-10-12 00:42 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2016-12-07 16:35 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2016-12-14 16:45 |
|
Articles in Press |
|
2016-12-14 16:45 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2017-01-22 11:49 |
|
Publish the Manuscript Online |
|
2017-02-06 09:08 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Kenneth E Sherman, Minhee Kang, Richard Sterling, Triin Umbleja, Kristen Marks, Jennifer J Kiser, Beverly Alston-Smith, Wayne Greaves, Adeel A Butt and the ACTG 5294 BIRTH Study Team |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Kenneth E Sherman, MD, PhD, Gould Professor of Medicine, Division of Digestive Diseases, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, United States. kenneth.sherman@uc.edu |
| Key Words |
human immunodeficiency virus; hepatitis C virus; Boceprevir; Pegylated interferon alfa; Ribavirin |
| Core Tip |
Approval of first generation hepatitis C virus (HCV) protease inhibitors has initiated a change in care of HCV infected patients. Phase 2 trials in HCV/human immunodeficiency virus coinfected patients have sug-gested improved efficacy and tolerability for regimens that combined pegylated interferon (PEG-IFN) + ribavirin (RBV) with either boceprevir or telaprevir. We evaluated an HCV treatment regimen using a first generation HCV protease inhibitor (boceprevir) with PEG-IFN, and weight-based RBV in a phase 3 treatment trial, including HCV treatment-na?ve and treatment-experienced coinfected subjects. While sustained viral response rates were low overall they did exceed historical PEG-IFN/RBV rates. Use of new interferon-free direct acting antiviral agents modalities in this population is indicated. |
| Publish Date |
2017-02-06 09:08 |
| Citation |
Sherman KE, Kang M, Sterling R, Umbleja T, Marks K, Kiser JJ, Alston-Smith B, Greaves W, Butt AA. Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection. World J Hepatol 2017; 9(4): 217-223 |
| URL |
http://www.wjgnet.com/1948-5182/full/v9/i4/217.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v9.i4.217 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
